Gene Therapy Immunogenicity - Virtual Summit

Memo

Immunogenicity compromises both the efficacy and safety of gene therapies and thus represents one of the most prominent challenges that must be overcome in the field. Uniting translational, clinical, regulatory and manufacturing gene therapy functions, the inaugural Gene Therapy Immunogenicity Summit is the industry's definitive meeting enabling you to better measure, modulate and predict immune response and drive transformative treatments through the clinic to patients more quickly and efficiently. Key topics of discussion include:Evaluating the suitability and success of current immunosuppression agents in the context of gene therapyEmploying risk assessment tools to develop clinical bioanalytical and immunogenicity monitoring strategiesDissecting the immunogenicity of gene therapy vectors to better understand immunology safety concernsBetter understanding the innate immune response and its implications for gene therapy transductionEvaluating the resolution and throughput of technologies to define empty vs full capsid presenceImplementing the use of preclinical risk assessment tools to drive clinical immunogenicity strategies for gene therapy modalitiesWhat the implications are for the safety and efficacy of gene therapies if re-dosing is to occur URLs:Tickets: https://go.evvnt.com/614539-2?pid=5569Brochure: https://go.evvnt.com/614539-3?pid=5569 Prices:Conference Ticket (1st Release): USD 1399.0,Conference Ticket (2nd Release): USD 1599.0,Conference Ticket (3rd Release): USD 1799.0,Conference Ticket (Final Release): USD 1999.0 Speakers: Barry Byrne, Professor and Associate Chairman, University of Florida, Mark Milton, Area Head of Ophthalmology, Novartis, Sander van Deventer, Executive Vice President, uniQure, Martin Childers, Chief Medical Officer, Asklepios BioPharmaceutical, Roland Herzog, Professor of Pediatrics, Indiana University School of Medicine, Klaudia Kuranda, Immunology Leader, Spark Therapeutics, David Favre, Vice President Translational Medicine, Asklepios BioPharmaceutical, Boris Gorovits, Senior Director, Pfizer, Genine Winslow, Founder and Chief Executive Officer, Chameleon Biosciences, Rune Kjeken, Director - Technical and Advanced Therapies, Norwegian Medicines Agency, Takashi Kishimoto, Chief Scientific Officer, Selecta Biosciences Inc., Brian Long, Associate Director, BioMarin, Casey Case, President Research and Development, 4D Molecular Therapeutics, Ying Kai Chan, Chief Scientific Officer, Allyx Therapeutics, Pierre Burguiere, Director - Analytical Development and Nonclinical Research, GenSight Biologics, Korinna Henseleit, Senior Bioanalytical Scientist, Biogen, Tony Arulanadam, Vice President and Head of Gene Therapy Nonclinical Research, PTC Therapeutics, Yanmei Lu, Senior Director Bioanalytical Sciences, Sangamo Therapeutics, Roberto Calcedo, Vice President Immunology and Safety, TouchDown Therapeutics, Andrew Melton, Senior Scientist II, BioMarin, Carsten Bonnemann, Senior Investigator, NIH, Liching Cao, Director Bioanalytical Operations, Sangamo Date and Time: On Tuesday August 04, 2020 at 8:00 am (ends Thursday August 06, 2020 at 5:30 pm)